Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

This new investment underscores Regeneron’s commitment to deliver innovative medicines to patients. Regeneron continues to invest heavily in its New York State operations, where an approximately ...